S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.75 (+1.13%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.75 (+1.13%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.75 (+1.13%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.75 (+1.13%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)

Immunovant (IMVT) Stock Forecast, Price & News

$20.91
-0.34 (-1.60%)
(As of 11:01 AM ET)
Compare
Today's Range
$20.80
$21.51
50-Day Range
$14.20
$23.75
52-Week Range
$3.14
$24.18
Volume
112,749 shs
Average Volume
1.02 million shs
Market Capitalization
$2.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.77

Immunovant MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
16.6% Upside
$24.77 Price Target
Short Interest
Bearish
8.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.08mentions of Immunovant in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$135,979 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.76) to ($1.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

909th out of 981 stocks

Biological Products, Except Diagnostic Industry

156th out of 165 stocks


IMVT stock logo

About Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Immunovant (NASDAQ:IMVT) Shares Up 10% After Analyst Upgrade
H.C. Wainwright Keeps Their Buy Rating on Immunovant (IMVT)
Recap: Immunovant Q4 Earnings
LifeSci Capital Keeps Their Buy Rating on Immunovant (IMVT)
See More Headlines

IMVT Price History

IMVT Company Calendar

Last Earnings
5/22/2023
Today
6/08/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.77
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+16.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$-210,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.78 per share

Miscellaneous

Free Float
126,496,000
Market Cap
$2.77 billion
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Dr. Frank M. Torti M.B.A. (Age 44)
    M.D., MBA, Exec. Chairperson of the Board
    Comp: $94.11k
  • Dr. Peter Salzmann M.B.A.Dr. Peter Salzmann M.B.A. (Age 55)
    M.D., CEO & Director
    Comp: $979.96k
  • Ms. Eva Renee Barnett M.B.A. (Age 43)
    Chief Financial Officer
    Comp: $534.98k
  • Dr. William L. Macias M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $4.85M
  • Dr. Julia G. Butchko Ph.D. (Age 52)
    Chief Devel. & Technology Officer
  • Dr. Chau Cheng M.B.A.
    Ph.D., VP of Investor Relations
  • Mr. Mark S. Levine (Age 50)
    Chief Legal Officer & Corp. Sec.
  • Ms. Lauren Schrier M.B.A.
    VP of Marketing













IMVT Stock - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings
or view top-rated stocks.

What is Immunovant's stock price forecast for 2023?

11 brokers have issued twelve-month target prices for Immunovant's shares. Their IMVT share price forecasts range from $5.00 to $32.00. On average, they predict the company's stock price to reach $24.77 in the next twelve months. This suggests a possible upside of 16.6% from the stock's current price.
View analysts price targets for IMVT
or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2023?

Immunovant's stock was trading at $17.75 at the beginning of the year. Since then, IMVT stock has increased by 19.7% and is now trading at $21.25.
View the best growth stocks for 2023 here
.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IMVT earnings forecast
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) posted its earnings results on Monday, May, 22nd. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.05.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (3.18%), State Street Corp (3.05%), BlackRock Inc. (3.02%), Logos Global Management LP (1.92%), Commodore Capital LP (1.11%) and Perceptive Advisors LLC (0.99%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends
.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $21.25.

How much money does Immunovant make?

Immunovant (NASDAQ:IMVT) has a market capitalization of $2.77 billion. The company earns $-210,960,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via phone at 917-580-3099 or via email at info@immunovant.com.

This page (NASDAQ:IMVT) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -